Venglustat malate is under clinical development by Sanofi and currently in Phase III for GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency). According to GlobalData, Phase III drugs for GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Venglustat malate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Venglustat malate overview
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi‘s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of Venglustat malate’s drug-specific PTSR and LoA scores, buy the report here.